Results 161 to 170 of about 71,405 (265)

TCF/LEF family transcription factors: Molecular landscape and prognostic scoring in pan‐cancer

Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.
This study provides a comprehensive molecular landscape of TCF/LEF family transcription factors across 33 cancer types. We developed a TCF/LEF‐based prognostic score that correlates with immune infiltration, metabolic reprogramming and drug sensitivity, offering a robust transcriptomic signature for predicting patient survival and therapeutic response.
Zhengjun Yang, D. Q. Cai, Zhen Zhao, Zhixiang Jian, Mude Shi, Yajin Chen, Jueming Chen, Chunhua Qu, Diankui Cai   +8 more
wiley   +1 more source

Clinical Management of Helicobacter Infection in Captive Baboons (Papio anubis and Papio hamadryas), and Isolation and Molecular Characterization of Three Novel Helicobacter Species

Journal of Medical Primatology, Volume 55, Issue 4, August 2026.
ABSTRACT Background Helicobacter spp. are gastric or enterohepatic bacteria that can be commensal, opportunistic, or pathogenic. Few studies have evaluated Helicobacter spp. in baboons. Methods Twenty‐seven captive baboons were surveyed for Helicobacter spp. by fecal PCR, and a subset evaluated by culture.
Isabel A. Jimenez, Courtney Lunger, Marcus J. Crim, Shannon L. Primm, Anthony Mannion, Nathan P. Crilly, Lydia M. Hopper, Lindsey G. Thurman, Linnette L. Vasquez, Cory Brayton, Yan Feng, James G. Fox, Zeli Shen, Jessica M. Izzi   +13 more
wiley   +1 more source

A subset of high‐grade sarcomas with myogenic differentiation are associated with recurrent FGFR fusions

The Journal of Pathology: Clinical Research, Volume 12, Issue 4, July 2026.
Abstract Recurrent fusions involving FGFR1‐4 genes have been previously described in rare subsets of mostly benign chondroid and mesenchymal neoplasms involving bone and soft tissue. However, a more comprehensive analysis of sarcomas associated with FGFR fusions, including their incidence and histotypes, has not been performed.
Maximus CF Yeung, Carla Saoud, Sarah Chiang, Meera Hameed, Cristina R Antonescu   +4 more
wiley   +1 more source

Research on Targeted Therapy for Malignant Tumors of the Biliary Tract. [PDF]

Onco Targets Ther
Yang Y, Zhong H, Zhang J, Wang P.
europepmc   +1 more source

An Arterial‐Enhancing Liver Nodule With Washout in a Patient With Metabolic and Alcohol‐Associated Liver Disease

Journal of Gastroenterology and Hepatology, EarlyView.
Soon Kyu Lee, Sun Young Jun, Young Chul Yoon   +2 more
wiley   +1 more source

Differentiating the Clinical and Variant Spectrum of Hardikar Syndrome From Other MED12 ‐Related Developmental Disorders

American Journal of Medical Genetics Part A, Volume 200, Issue 7, Page 1619-1650, July 2026.
ABSTRACT The rare X‐linked female‐restricted Hardikar syndrome (HDKR, OMIM # 301068) is characterized by multiple congenital anomalies including orofacial clefts, gastrointestinal, genitourinary, and cardiac anomalies, but cognitive and neurobehavioral development is rarely impaired.
Tinne Warmoeskerken, Miel Theunis, Kris Van den Bogaert, Koenraad Devriendt, Jeroen Breckpot   +4 more
wiley   +1 more source

Impact of Multimodal Oncological Therapy on Survival and Local Control in Unresectable Perihilar Cholangiocarcinoma

Cancer Medicine, Volume 15, Issue 7, July 2026.
ABSTRACT Background This study aimed to evaluate the safety and effectiveness of targeted multimodal oncological therapy in patients with unresectable hilar cholangiocarcinoma (HCCA) presenting with obstructive jaundice, particularly those with the nodular‐infiltrating morphological type.
Zhen Chi, Lihong Chen, Weizhu Yang, Ning Huang, Jingyao Huang, Fenglin Chen   +5 more
wiley   +1 more source

Treatment Outcomes of Hospitalized Patients With Inflammatory Bowel Disease at a Tertiary Care Center in Nepal: A Cross‐Sectional Study

JCC Plus, Volume 1, Issue 4, July 2026.
Overall, patients with IBD constituted 1.6% (n = 37) of all admissions to the gastroenterology ward for any indication. Most (2/3rd) hospitalized patients with IBD responded to conventional therapy; one third required advanced therapy or surgery. In‐hospital mortality was high at 5%, probably related to delayed diagnosis, limited access to advanced ...
Ajay Kumar Yadav, Bhupendra Kumar Basnet, Ramila Shrestha, Ajit Khanal, Milan Shrestha, Mukesh Sharma Poudel   +5 more
wiley   +1 more source

RNA Modifications in Tumor Microenvironment: A New Dimension for Cancer Treatment

MedComm, Volume 7, Issue 7, July 2026.
Tumor initiation and progression depend on a supportive and highly heterogeneous tumor microenvironment (TME). RNA modifications regulate signaling pathways and cytokine networks that shape TME dynamics, facilitating interactions between cancer cells and noncancerous stromal cells, and ultimately promoting immune evasion and tumor progression ...
Qiwen Li, Yating Sun, Shuibin Lin, Quan Yuan   +3 more
wiley   +1 more source

Drug Interactions of Vebreltinib, a Novel Type I c‐Met Inhibitor, Coadministration With Rifampin or Itraconazole in Healthy Participants

Clinical and Translational Science, Volume 19, Issue 7, July 2026.
Pharmacokinetic and drug–drug interaction evaluation of vebreltinib in healthy participants, showing decreased exposure with rifampin and increased exposure with itraconazole. ABSTRACT Vebreltinib is a novel, highly selective type I c‐Met inhibitor developed for treating non–small cell lung cancer (NSCLC) and glioma.
Jingcheng Chen, Jingxuan Wu, Yuqin Song, Jiangshuo Li, Linna li, Lijun Li, Yanhong Kong, Xiaofang Wu, Hang Yin, Mengyu Hou, Bingyan Wang, Qiannan Gao, Ran Li, Le Wu, Weizhe Xue, Ruihua Dong   +15 more
wiley   +1 more source